Valsartan Lawsuit 2026: The $15.2 Million Settlement Is Closed, Cancer Claims Are Still Pending, and the Claim Deadline Has Passed
Quick Answer
- The Valsartan lawsuit involves real settlements: Hetero ($11.36M), Aurobindo ($2M), and Vivimed ($1.9M) were approved in 2026.
- The claim deadline was June 2, 2026, and it has passed, so new claims are no longer accepted.
- Cancer injury claims remain unresolved, with no settlement fund and no confirmed payout timeline.
You searched for the Valsartan lawsuit because you took a recalled blood pressure pill and you want to know if money is still available. Here is the direct answer: the economic-loss settlements are real, but the deadline to claim was June 2, 2026, and it is gone .
The recalls began in July 2018, when the FDA found nitrosamine impurities, including NDMA and NDEA, in generic valsartan made with certain manufacturing processes . The FDA estimated a worst-case risk of one additional cancer case per 8,000 people exposed to the highest dose for four years .
The number that matters most now is 1,426. That is how many personal injury cases remained pending in the MDL as of October 2026, according to settlement tracking . Those cases have no fund, no deadline, and no payout date.
This article breaks down what was settled, who was covered, why the deadline closed, what cancer claimants can still do, and how to spot fake Valsartan claim offers.
The Facts
| Item | Detail |
|---|---|
| Case | In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation |
| Court | U.S. District Court, District of New Jersey |
| Case Number | 1:19-md-02875 |
| Status | Economic-loss settlements approved July 2026; personal injury cases pending |
| Fund Size | $15.2 million combined (Hetero $11.36M, Aurobindo $2M, Vivimed $1.9M) |
| Est. Per Person | Not yet determined; depends on valid claims filed by June 2, 2026 |
| Claim Deadline | June 2, 2026 (closed) |
| Administrator | EAG Gulf Coast, LLC |
| Proof Needed | Proof of purchase for economic-loss claims; medical records for injury claims |
Is the Valsartan Lawsuit Real or a Scam?
The Valsartan lawsuit is real, and the settlements are documented in federal court records. The MDL is pending in the District of New Jersey under Chief Judge Renee Marie Bumb, and final approval orders for the Hetero and Vivimed settlements were entered in July 2026 .
But real does not mean open. The claim deadline for the economic-loss settlements was June 2, 2026, and it has passed . If a page tells you to file a Valsartan claim today, it is either outdated or trying to collect your information.
The scam angle is common with drug recalls because the names are recognizable and the fear is real. Pages promise “Valsartan settlement payouts” and ask for your Medicare number or a processing fee. The legitimate process required a court-approved claim form and proof of purchase, and it closed months ago.
Key Takeaway: The Valsartan settlements are real and court-approved, but the claim window closed on June 2, 2026, and no new claims are accepted.
How Much Was the Valsartan Settlement?
The Valsartan economic-loss settlements totaled approximately $15.2 million across three manufacturers. Hetero agreed to pay $11,365,489.80 for valsartan, Aurobindo agreed to pay $2,000,000 for irbesartan, and Vivimed agreed to pay $1,899,000 for losartan .
These settlements covered economic losses, not personal injuries. The theory was that consumers and third-party payors paid money for drugs that were contaminated and therefore worth less than what they paid. The court limited that theory, excluding a “zero-value” damages argument, which narrowed what claimants could recover .
| Manufacturer | Drug | Settlement Amount |
|---|---|---|
| Hetero | Valsartan | $11,365,489.80 |
| Aurobindo | Irbesartan | $2,000,000 |
| Vivimed | Losartan | $1,899,000 |
| Combined | ~$15.2 million |
Not yet determined: Per-person payout amounts. The settlement website had not announced a payment date as of October 2026 .
Reality Check
Reality Check: No one texts you Valsartan settlement money. The claim deadline passed on June 2, 2026, and the administrator is not accepting new forms. If a page asks for your Medicare number or a fee to “reopen” your Valsartan claim, it is a scam. Real settlement notices come from court-approved administrators and official websites, not social media ads.
Who Qualified for the Valsartan Settlement?
You may have qualified for the economic-loss settlement if you purchased specific contaminated generic valsartan, irbesartan, or losartan during the recall window. The Hetero settlement covered valsartan made with Hetero Process III active ingredient purchased between May 1, 2018 and July 31, 2018 .
The class included individual consumers and third-party payors like insurance companies. Proof of purchase was requested, though the claim form allowed consumers to identify the product if possible without making it an absolute condition .
The settlement did not cover brand-name Diovan. It covered generic versions made by the settling manufacturers. It also did not resolve cancer claims, which are a separate track in the MDL.
Why Is There No Valsartan Lawsuit Claim Form Available Now?
There is no claim form available now because the deadline closed on June 2, 2026 . The settlement website launched in April 2026, the claim period ran through early June, and the final approval hearing was held on June 30, 2026 .
The court entered final approval for the Hetero settlement on July 6, 2026 . Final approval for the Vivimed settlement followed. Once those orders were entered, the claims process moved to review and validation, not new filing.
If you missed the deadline, you cannot file a late claim through the official process. You can check the settlement website for any announced exceptions, but none were confirmed as of October 2026.
What About the Valsartan Cancer Lawsuits?
The cancer lawsuits are separate from the economic-loss settlements and remain unresolved. As of October 2026, 1,426 MDL cases were still pending, most of them personal injury claims alleging that nitrosamine exposure caused cancer .
The personal injury track has faced setbacks. The first bellwether trial ended when the court excluded the plaintiff’s specific causation expert in the Roberts case . That ruling did not kill the litigation, but it narrowed the path for individual plaintiffs. General causation experts survived, meaning the science linking NDMA to cancer in general was allowed. Specific causation, the link in each individual plaintiff, is the harder question.
A separate agreement in principle was reached in April 2026 between plaintiffs and the Aurobindo defendants to establish a personal injury settlement program for Aurobindo valsartan claims filed or registered by April 8, 2026 . That settlement has not been documented or approved, and no claim deadline or payout figure has been announced.
Key Takeaway: Cancer claims are still active but have no settlement fund, no approved payout, and no public claim deadline yet.
What Happens Next in the Valsartan Litigation?
The economic-loss settlements are in the payment administration phase. The personal injury cases are moving through bellwether selection and settlement talks.
July 2026: Final approval orders entered for Hetero and Vivimed settlements .
Expected late 2026: Claims review and validation for the approved settlements. No payment date announced.
Expected 2026 or later: Wave Three bellwether selection for remaining personal injury cases. Aurobindo personal injury settlement to be documented and submitted for approval .
Not yet confirmed: Payment dates for economic-loss claims, and any settlement structure for the remaining cancer claims.
If you filed a timely economic-loss claim, watch the official settlement website for payment updates. If you have a cancer claim, consult a lawyer about your individual case and the Aurobindo settlement process.
Frequently Asked Questions
Is the Valsartan lawsuit real?
Yes. The MDL is pending in New Jersey federal court, and three economic-loss settlements received final approval in 2026.
Can I still file a Valsartan claim?
No. The claim deadline was June 2, 2026, and it has passed.
How much was the Valsartan settlement?
The combined economic-loss settlements totaled about $15.2 million across Hetero, Aurobindo, and Vivimed.
When will Valsartan settlement payments go out?
Not yet determined. The settlement website had not announced a payment date as of October 2026.
What if I got cancer from Valsartan?
Cancer claims are separate from the economic-loss settlements. They remain pending, with no approved fund or claim deadline.
Did the FDA recall Valsartan?
Yes. The FDA announced recalls of certain generic valsartan, losartan, and irbesartan products starting in 2018 due to nitrosamine impurities.
Was brand-name Diovan part of the lawsuit?
No. The litigation centers on generic valsartan made by specific manufacturers, not brand-name Diovan.
Where can I check my Valsartan claim status?
Use the official settlement website and the court-approved administrator, EAG Gulf Coast, LLC. Do not rely on third-party claim services.
The Bottom Line
The Valsartan lawsuit produced real settlements, but the money for economic-loss claims is closed to new filers. The deadline was June 2, 2026. Cancer claims remain active with no fund and no deadline. If you filed a claim, watch the official settlement site. If you have a cancer claim, talk to a lawyer about the pending Aurobindo process.
